Nobuyuki Ishige

Mr. Nobuyuki Ishige

Assistant manager
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

Verified
Journal Article
Open access
PDF file
YSYosuke Shigematsu
Yosuke Shigematsu
MYMiori Yuasa
Miori Yuasa
NINobuyuki Ishige
Nobuyuki Ishige
HNHideki Nakajima
Hideki Nakajima
GTGo Tajima
Go Tajima
To minimize false-positive cases in newborn screening by tandem mass spectrometry in Japan, practical second-tier liquid chromatography-tandem mass spectrometry analyses have been developed using a multimode ODS column with a single set of mobile phases and different gradient elution programs specific to the analysis of acylcarnitines, acylglycines, amino acids, and organic acids. Most analyses were performed using underivatized samples, except for analysis of methylcitric acid, and careful conditioning of the column was necessary for analyses of organic acids. Our second-tier tests enabled us to measure many metabolites useful for detection of target disorders, including allo-isoleucine, homocysteine, methylmalonic acid, and methylcitric acid. We found that accumulation of 3-hydroxyglutaric acid was specific to glutaric acidemia type I and that the ratio of 3-hydroxyisovaleric acid to 3-hydroxyisovalerylcarnitine was useful to detect newborns of mothers with 3-methylcrotonyl-CoA carboxylase deficiency. Data from the analysis of short-chain acylcarnitine and acylglycine were useful for differential diagnosis in cases positive for C5-OH-acylcarnitine or C5-acylcarnitine.

1 November 2015 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
KYKenji Yamada
Kenji Yamada
HKHironori Kobayashi
Hironori Kobayashi
RBRyosuke Bo
Ryosuke Bo
TTTomoo Takahashi
Tomoo Takahashi
YHYuki Hasegawa
Yuki Hasegawa
SYSeiji Yamaguchi
Seiji Yamaguchi

Verified
Journal Article
Open access
PDF file
GTGo Tajima
Go Tajima
NINobuyuki Ishige
Nobuyuki Ishige
JHJunji Hanai
Junji Hanai
KKKeiko Konomura
Keiko Konomura
False-positive results are known to occur frequently in newborn screening (NBS) for carnitine palmitoyltransferase II (CPT II) deficiency, highlighting the need to identify appropriate screening markers. The present study aimed to compare the performance of two markers currently used in NBS for CPT II deficiency, (C16 + C18:1)/C2 and C14/C3, with two promising alternative markers, C12/C0 and C12/C2. We analyzed non-patient data from the 2023 fiscal year NBS program together with patient data for CPT II deficiency and very-long-chain acyl-CoA dehydrogenase deficiency derived from previously reported case series. Marker performance was assessed using precision–recall curves, including an analysis in which patients with the myopathic form of CPT II deficiency who passed NBS using (C16 + C18:1)/C2 and C14/C3 were reclassified as true positives. The area under the precision–recall curve values for C12/C2 and C14/C3 were 0.711 (95% confidence interval, 0.492–0.923) and 0.569 (0.341–0.779), respectively, indicating superior performance compared with the other markers. When cases with the myopathic form of CPT II deficiency were included as true positives, the performance of all markers decreased markedly. Although some patients with the myopathic form are still likely to be missed, C12/C2 appears to be an effective marker for reducing false-positive results.

17 August 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
TNTsubasa Nishinosono
Tsubasa Nishinosono
HMHideki Muramatsu
Hideki Muramatsu
MWManabu Wakamatsu
Manabu Wakamatsu
NINobuyuki Ishige
Nobuyuki Ishige
JHJunji Hanai
Junji Hanai
KIKohsuke Imai
Kohsuke Imai
Large-scale real-world data on T-cell receptor excision circle (TREC)– and κ-deleting recombination excision circle (KREC)–based newborn screening for inborn errors of immunity remain limited. In this nationwide cohort, we evaluated Japan’s program (2020–2025), including 1,380,634 newborns. Of 869 referred infants (0.06%), 40 were diagnosed, including 15 with severe combined immunodeficiency (SCID), 16 with X-linked agammaglobulinemia or other agammaglobulinemias, and nine with severe T cell lymphopenia. After a median follow-up of 18 mo, overall survival was 98%. All infants with SCID survived; 14 underwent hematopoietic cell transplantation with sustained engraftment. Referral rates were 0.04% for TREC and 0.03% for KREC. Repeat sampling was associated with lower referral rates (0.05 vs. 0.56%). Referral rates varied across assay kits and laboratory practices, reflecting interlaboratory heterogeneity in a decentralized screening system. The transition from self-paid to public funding increased coverage from 77.1 to 97.7%. These findings support TREC/KREC-based screening and highlight the need for standardized algorithms and sustained public funding for equitable nationwide implementation.

Verified
Journal Article
Open access
PDF file
RMRyuichi Mashima
Ryuichi Mashima
NINobuyuki Ishige
Nobuyuki Ishige
Biomarkers with potential for use in clinical diagnosis have been widely studied using biochemical techniques. In particular, endogenous and exogenous metabolites have been targeted in clinical settings. Both types of metabolites are either unmetabolized, metabolized with human enzymes, or metabolized with host-resident bacterial enzymes. In standard clinical chemistry, a specimen must be collected following overnight fasting to minimize the effect of dietary input and the subsequent host and microbial metabolism. Current technology allows the detection of nanomolar concentrations of exogenously derived biomarkers, and these ultra-high sensitivity assays have increased the use of trace amounts of such biomarkers. This narrative review explores how the gut–liver–kidney axis modulates disease manifestation and biomarker accumulations in chronic disorders and inborn errors of metabolism in neonates.